Improving Clinical Efficiency by Reducing Scheduled Follow-ups Using Cochlear America’s Population Mean Mapping Strategy

by palligoelme@gmail.com | May 9, 2025 | Clinical Trials

​ Conditions: Deafness; Cochlear Hearing Loss Interventions: Other: Changes in traditional follow-up; Other: Population mean mapping Sponsors: Massachusetts Eye and Ear Infirmary; Cochlear Recruiting Conditions: Deafness; Cochlear Hearing Loss Interventions: Other:...

Cognitive Rehabilitation of Deficits in Patients With Multiple Sclerosis

by palligoelme@gmail.com | May 9, 2025 | Clinical Trials

​ Conditions: Telerehabilitation; Multiple Sclerosis; Cognitive Disorders; Neurorehabilitation Interventions: Behavioral: Cognitive treatment delivered via telerehabilitation.; Behavioral: In-person cognitive treatment. Sponsors: Universita di Verona...

Expiratory Muscle Training and Trunk Flexion in Parkinson’s Disease

by palligoelme@gmail.com | May 9, 2025 | Clinical Trials

​ Conditions: Parkinson Disease Interventions: Device: Expiratory muscle strength training Sponsors: General University Hospital, Prague Not yet recruiting Conditions: Parkinson Disease Interventions: Device: Expiratory muscle strength training Sponsors: General...

The Use of Artificial Intelligence Generated Contours in Radiation Planning of the Prostate Brachytherapy

by palligoelme@gmail.com | May 9, 2025 | Clinical Trials

​ Conditions: Prostate Cancer Interventions: Other: Artificial-intelligence (AI) Sponsors: Martin King, MD, PhD Not yet recruiting Conditions: Prostate Cancer Interventions: Other: Artificial-intelligence (AI) Sponsors: Martin King, MD, PhD Not yet...

A Study to Understand the Patients Confirmed to Have Advanced or Metastatic Breast Cancer and Receiving Palbociclib Treatment Using a Real-world Database

by palligoelme@gmail.com | May 8, 2025 | Clinical Trials

​ Conditions: Advanced or Metastatic Breast Cancer Interventions: Drug: Ibrance Sponsors: Pfizer Not yet recruiting Conditions: Advanced or Metastatic Breast Cancer Interventions: Drug: Ibrance Sponsors: Pfizer Not yet...